CLAIMS

1. Use of an effective amount of an antibody in the manufacture of a medicament for treating rheumatoid arthritis in a subject, wherein the antibody comprises three complementarity determining regions (CDRs) of SEQ ID NO:2 and three CDRs of SEQ ID NO:3, wherein the subject was previously ineffectively treated for rheumatoid arthritis by administration of methotrexate.

2. The use of claim 1, wherein the antibody is to be administered at a dose of between 50 and 150 mg every week.

3. The use of any of claims 1 to 2, wherein the antibody is to be administered at a dose of between 100 and 200 mg every two weeks.

4. The use of any of claims 1 to 3, wherein the antibody is to be administered at a dose of 150 mg every two weeks or 200 mg every two weeks.

5. The use of claim 4, wherein the subject achieves at least a 20% improvement in the American College of Rheumatology (ACR) core set disease index after treatment.

6. The use of claim 5, wherein the subject achieves the improvement in the ACR core set disease index after 12 weeks of treatment.

7. The use of claim 5, wherein the subject achieves the improvement in the ACR core set disease index after 24 weeks of treatment.

8. The use of claim 4, wherein the subject achieves at least a 50% improvement in the American College of Rheumatology (ACR) core set disease index after treatment.

9. The use of claim 8, wherein the subject achieves the improvement in the ACR core set disease index after 12 weeks of treatment.

10. The use of claim 4, wherein the subject achieves at least a 70% improvement in the American College of Rheumatology (ACR) core set disease index after treatment.

11. The use of claim 10, wherein the subject achieves the improvement in the ACR core set disease index after 12 weeks of treatment.

12. The use of claim 4, wherein the subject achieves at least a 0.3 improvement in the Health Assessment Questionnaire Disability Index (HAQ-DI) after treatment.

13. The use of claim 12, wherein the subject achieves the improvement in HAQ-DI after 12 weeks of treatment.

14. The use of claim 4, wherein the subject achieves at least a decrease in Visual Acuity Score (VAS) of at least 30 after treatment as compared to baseline.

15. The use of claim 14, wherein the subject achieves the improvement in VAS after 12 weeks of treatment.

16. The use of claim 4, wherein the subject achieves at least a 1 mg/dL decrease in level of C-reactive protein (CRP) in blood sample and/or urine sample after treatment.

17. The use of claim 16, wherein the subject achieves the decrease in level of CRP after 12 weeks of treatment.

18. The use of claim 4, wherein the subject achieves an improvement in European League Against Rheumatism (EULAR) index after treatment.

19. The use of claim 18, wherein the subject achieves the improvement in EULAR index after 12 weeks of treatment.

20. The use of claim 4, wherein the subject achieves at least a 0.6 increase in disease activity score (DAS28) after treatment.

21. The use of claim 20, wherein the subject achieves the increase in DAS28 after 12 weeks of treatment.

22. The use of any one of claims 1-4, wherein the medicament further comprises methotrexate.

23. The use of claim 22, wherein the methotrexate is to be administered at a dose of between

6 to 25 mg per week.

24. The use of any of claims 1 to 23, wherein the antibody is sarilumab.

25. The use of any of claims 1 to 24, wherein the antibody is to be administered subcutaneously to the subject.